Challenges to promoting maternal respiratory syncytial virus vaccination in Japan
- PMID: 39848132
- DOI: 10.1016/j.vaccine.2025.126767
Challenges to promoting maternal respiratory syncytial virus vaccination in Japan
Abstract
Pfizer's Abrysvo vaccine is highly effective in preventing severe lower respiratory tract illness in those at high risk from the Respiratory Syncytial Virus (RSV). Japan, like other countries, is promoting RSV vaccination among pregnant women, but it needs to do better. However, Japan is enduring a state of broad vaccine hesitancy. In light of our experiences with Japan's past failures in promoting the Human Papillomavirus vaccine, we describe some of the challenges encountered in promoting vaccines and discuss possible solutions.
Keywords: Maternal vaccination; Promotion of vaccination; Respiratory syncytial virus.
Copyright © 2025 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
